Use: Labeled indications
- INDICATION AND USAGE Hypertension.
Full indications and usage US FDA label
INDICATION AND USAGE Hypertension.
Contraindications
CONTRAINDICATIONS Methyldopa is contraindicated in patients: — with active hepatic disease, such as acute hepatitis and active cirrhosis — with liver disorders previously associated with methyldopa therapy (see WARNINGS) — with hypersensitivity to any component of these products. — on therapy with monoamine oxidase (MAO) inhibitors.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION ADULTS Initiation of Therapy The usual starting dosage of Methyldopa is 250 mg two or three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than two days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening.
By adjustment of dosage, morning hypotension may be prevented without sacrificing control of afternoon blood pressure. When methyldopa is given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When Methyldopa is given with antihypertensives other than thiazides, the initial dosage of Methyldopa should be limited to 500 mg daily in divided doses; when Methyldopa is added to a thiazide, the dosage of thiazide need not be changed.
Maintenance Therapy The usual daily dosage of Methyldopa is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 g. Once an effective dosage range is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. Since methyldopa has a relatively short duration of action, withdrawal is followed by return of hypertension usually within 48 hours.
This is not complicated by an overshoot of blood pressure. Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of methyldopa frequently will restore effective control of blood pressure. A thiazide may be added at any time during methyldopa therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 g of methyldopa daily.
Methyldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses. (See PRECAUTIONS, Geriatric Use) PEDIATRIC PATIENTS Initial dosage is based on 10 mg/kg of body weight daily in two to four doses.
The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 g daily, whichever is less. (See PRECAUTIONS, Pediatric Use)
Dosing: Altered kidney function
Methyldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Film-coated tablet: 250 mg
- Tablet: 125 mg, 250 mg
Registered products in the Philippines
38 products registered with the Food and Drug Administration (FDA) Philippines list Methyldopa as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products38
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AldocoreMethyldopa | 250 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | S Kant Health Care LimitedIndia | Greencore Pharma Inc.Importer: Triple Tact Import & Export Corp. | DRP-13139-01 | Dec 9, 2027 | |
AldometMethyldopa | 250 mg TabletClear PVC/Alu Foil Blister Pack x 10's Box of 100's; Clear PVC/Alu Foil Blister Pack x 10's Box of 500's | RxVAT-exempt | Aspen Sa Operations (Pty) LtdRepublic of South Africa | Aspen Philippines Inc. | DR-XY39311 | Apr 12, 2031 | |
AldopiemMethyldopa | 250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Vivilon Pharmaceuticals Inc. | DRP-13715 | Mar 31, 2028 | |
AldowellMethyldopa | 250 mg Film-Coated TabletAlu/PVDC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | S Kant Healthcare Ltd.India | Wellchem Pharmaceutical Products | DRP-18828 | Sep 14, 2031 | |
AldrometMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-8968 | Aug 17, 2030 | |
BP LowMethyldopa | 250 mg TabletAlu/Amber PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | S Kant Healthcare LimitedIndia | Ambica International Corporation | DRP-7382 | Dec 18, 2029 | |
DomepaMethyldopa | 250 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Domesco Medical Import Export Joint-Stock CorporationVietnam | The Cathay Drug Co., Inc. | DR-XY45568 | Aug 26, 2031 | |
DopacareMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-3655 | May 27, 2031 | |
DopacareMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-9112 | Sep 14, 2030 | |
DopafixMethyldopa | 250 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | S Kant Healthcare LimitedIndia | Medvybe Pharmaceutical TradingImporter: Triple Tact Import & Export Corp. | DRP-13139-02 | Dec 9, 2027 | |
DopalinkMethyldopa (as Sesquihydrate) | 250 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Altomed Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc. | DRP-3655-02 | May 27, 2036 | |
DopalinkMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-9110 | Sep 14, 2030 | |
DopamaineMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Ultramed Pharma, Inc.Trader: Vamsler Phils., Inc. | DRP-5467-01 | Feb 25, 2030 | |
DopamaineMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Ultramed Pharma, Inc. | DRP-9303 | Aug 6, 2031 | |
DopametMethyldopa (as Sesquihydrate) | 250 mg Film-Coated TabletAlu-Alu Blister Pack x 8's (Box of 40's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY32301 | Sep 25, 2031 | |
DopametMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Euro-Health Care Exponents, Inc. | DRP-9129 | Sep 15, 2030 | |
DoparineMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-5467 | Feb 25, 2030 | |
DoparineMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-9109 | Sep 14, 2030 | |
DopathylMethyldopa (as Sesquihydrate) | 250 mg Film-Coated TabletAlu/Alu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Meedpharma Medical Supplies & Equipment DistributorTrader: Westfield Pharmaceuticals, Inc. | DRP-8568 | Jun 15, 2027 | |
HydometMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletFoil Strip Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Gamot Philippines, Inc. | DRP-5066 | Jul 28, 2031 | |
HydometMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Gamot Philippines, Inc. | DRP-9304 | Nov 24, 2030 | |
HymetMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-9111 | Sep 14, 2030 | |
HypnalMethyldopa | 125 mg TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | Trader: Vonwelt Inc. | DRP-1066 | Feb 27, 2027 | |
MedopaMethyldopa | 125mg TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | Drugmaker's Laboratories, Inc.Trader: Vonwelt, Inc. | DRP-1066-03 | Feb 27, 2027 | |
MethdosaphMethyldopa | 250 mg Film-Coated TabletAluminum Foil Strip Pack x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-14272 | Mar 26, 2031 | |
MetidolMethyldopa | 125 mg TabletAluminum Foil Strip x 10's Box of 100's | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-10465 | Sep 29, 2028 | |
MetilMethyldopa | 125 mg TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Vonwelt Inc. | DRP-1066-02 | Feb 27, 2027 | |
MetyenMethyldopa | 250 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Huazhong Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17780 | Mar 11, 2031 | |
MydopaMethyldopa | 250 mg Film-Coated TabletAlu/PVC blister pack x 10’s (Box of 100's) | RxVAT-exempt | S Kant Healthcare LimitedIndia | Triple Tact Import & Export Corp. | DRP-13139 | Dec 9, 2027 | |
NoneMethyldopa | 250 mg TabletAlu Strip Foil x 10’s Box of 100’s | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-5679 | Feb 28, 2029 | |
PrevadopaMethyldopa | 250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-13715-01 | Mar 31, 2028 | |
ThylometMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Euro-Health Care Exponents, Inc.Trader: Gamot Philippines, Inc. | DRP-5066-02 | Aug 18, 2031 | |
TildopaMethyldopa | 250 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | S Kant Healthcare LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-7382-02 | Dec 18, 2029 | |
TomedylMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Gamot Philippines, Inc. | DRP-5066-03 | Aug 27, 2031 | |
UnbrandedMethyldopa (as sesquihydrate) | 250 mg Film-Coated TabletAlu/Poly Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | — | DRP-9792 | Jun 7, 2031 | |
UnbrandedMethyldopa | 250 mg TabletAlu/Amber PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | S Kant Healthcare Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7382-01 | Dec 18, 2029 | |
XylodopaMethyldopa | 250 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15934 | Oct 2, 2029 | |
(no brand name)Methyldopa | 250 mg Film-Coated TabletAlu/Clear PVC Film Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Vivilon Pharmaceuticals, Inc. | DRP-13775 | Apr 17, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS It is important to recognize that a positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy. The rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions.
With prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy. Lowest incidence is at daily dosage of 1 g or less. This on rare occasions may be associated with hemolytic anemia, which could lead to potentially fatal complications.
One cannot predict which patients with a positive direct Coombs test may develop hemolytic anemia. Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, the physician should determine whether hemolytic anemia exists and whether the positive Coombs test may be a problem.
For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood. Before treatment is started, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is anemia.
Periodic blood counts should be done during therapy to detect hemolytic anemia. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy. If Coombs-positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued. Usually the anemia remits promptly.
If not, corticosteroids may be given and other causes of anemia should be considered. If the hemolytic anemia is related to methyldopa, the drug should not be reinstituted. When methyldopa causes Coombs positivity alone or with hemolytic anemia, the red cell is usually coated with gamma globulin of the IgG (gamma G) class only.
The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped. Should the need for transfusion arise in a patient receiving methyldopa, both a direct and an indirect Coombs test should be performed. In the absence of hemolytic anemia, usually only the direct Coombs test will be positive.
A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed. Occasionally, fever has occurred within the first 3 weeks of methyldopa therapy, associated in some cases with eosinophilia or abnormalities in one or more liver function tests, such as serum alkaline phosphatase, serum transaminases (SGOT, SGPT), bilirubin, and prothrombin time.
Jaundice, with or without fever, may occur with onset usually within the first 2 to 3 months of therapy. In some patients the findings are consistent with those of cholestasis. In others the findings are consistent with hepatitis and hepatocellular injury. Rarely, fatal hepatic necrosis has been reported after use of methyldopa.
These hepatic changes may represent hypersensitivity reactions. Periodic determinations of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained fever occurs. If fever, abnormalities in liver function tests, or jaundice appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued.
Methyldopa should not be reinstituted in such patients. Rarely, a reversible reduction of the white blood cell count with a primary effect on the granulocytes has been seen. The granulocyte count returned promptly to normal on discontinuance of the drug. Rare cases of granulocytopenia have been reported. In each instance, upon stopping the drug, the white cell count returned to normal.
Reversible thrombocytopenia has occurred rarely.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. However, significant adverse effects due to Methyldopa have been infrequent and this agent usually is well tolerated.
The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia.
Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or “black” tongue, nausea, constipation, distension, flatus, dryness of mouth. Endocrine: Hyperprolactinemia. Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test.
Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests (see WARNINGS). Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia. Nervous System/Psychiatric: Parkinsonism, Bell's palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizziness, lightheadedness, paresthesias.
Metabolic: Rise in BUN. Musculoskeletal: Arthralgia, with or without joint swelling; myalgia. Respiratory: Nasal stuffiness. Skin: Toxic epidermal necrolysis, rash. Urogenital: Amenorrhea, breast enlargement, gynecomastia, lactation, impotence, decreased libido.
Pharmacokinetics
The known urinary metabolites are: α-methyldopa mono-0-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates.
Approximately 70% of the drug which is absorbed is excreted in the urine as methyldopa and its mono-0-sulfate conjugate.
The renal clearance is about 130 mL/min in normal subjects and is diminished in renal insufficiency.
The plasma half-life of methyldopa is 105 minutes.
After oral doses, excretion is essentially complete in 36 hours.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity.
Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine. Only methyldopa, the L -isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L -isomer.
About twice the dose of the racemate (DL -alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration.
In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Pharmacokinetics and Metabolism The maximum decrease in blood pressure occurs four to six hours after oral dosage. Once an effective dosage level is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. After withdrawal, blood pressure usually returns to pretreatment levels within 24-48 hours.
Methyldopa is extensively metabolized. The known urinary metabolites are: α-methyldopa mono-0-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates. Approximately 70% of the drug which is absorbed is excreted in the urine as methyldopa and its mono-0-sulfate conjugate.
The renal clearance is about 130 mL/min in normal subjects and is diminished in renal insufficiency. The plasma half-life of methyldopa is 105 minutes. After oral doses, excretion is essentially complete in 36 hours. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Methyldopa 250 mg Tablet | ₱4.86–₱11.00Reference ₱9.18 | per tablet | DPRI procurement range |
| 250 mg tablet | ₱11.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Methyldopa |
| PNF listing | Oral: 250 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Methyldopa · Chartwell RX, LLC [US FDA-approved label, version 3, March 26, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1114a58-9ab5-486e-85ed-360365b06396
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .